HuMod is the parent company behind Genesis Dynamics, its first operating program: a human-machine systems platform focused on advanced lower-limb prosthetics. The flagship product, the Genesis Ankle (GEN-5), is an AI-powered prosthetic ankle that delivers full biological ankle motion, active push-off through the gait cycle, and onboard intelligence — all at a wholesale price of $4,499, far below incumbent solutions priced at $20,000+. Genesis is purpose-built to fit inside existing Medicare and commercial payer reimbursement infrastructure (L5973 billing code, up to $50K reimbursement), enabling clinics to earn strong margins on every fitting without changing payer behavior. Every deployed unit feeds a proprietary data flywheel that continuously improves device performance via OTA updates, creating a compounding moat that grows with scale.
See something off about this company?
Joseph Kaisner
founder
Approximately 2 million Americans live with lower-limb loss, yet fewer than 1% use advanced powered prosthetic systems. While payer reimbursement infrastructure already exists (up to $20K per device), current powered ankles cost $20,000+ to deliver, making them structurally inaccessible for most clinics and patients.
The Genesis Ankle (GEN-5) delivers full active powered ankle motion with onboard edge AI, no body-worn sensors, and OTA software updates — wholesaled to clinics at $4,499. Clinics bill L5973 and capture the reimbursement spread, creating immediate margin without changing payer behavior. Each deployed unit instruments real-world gait data, continuously retraining models and improving performance across the entire fleet.
Pre-seed closed Q2 2025 with under $1M deployed to date. The team has built a patent-pending mechatronic stack, proprietary adaptive edge models, telemetry and OTA architecture, and early onshore manufacturing. Regulatory pathway cleared (DLA Piper); FDA and PDAC pathway in active execution. $565K of the $1.5M seed target already wired (SAFE). First clinical partner deployments targeted Q3 2026.